Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.

Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, Antman EM, Braunwald E, Giugliano RP.

Hypertension. 2019 Sep;74(3):597-605. doi: 10.1161/HYPERTENSIONAHA.119.13138. Epub 2019 Jul 29.

PMID:
31352829
2.

Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.

Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2019 Jul 16;74(2):179-189. doi: 10.1016/j.jacc.2019.04.061.

PMID:
31296289
3.

Response.

Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel.

Chest. 2019 Jun;155(6):1311-1312. doi: 10.1016/j.chest.2019.03.037. No abstract available.

PMID:
31174653
4.

Response.

Lip GYH, Ruff CT, Moores L; 2018 CHEST Guideline Expert Panel.

Chest. 2019 Jun;155(6):1309. doi: 10.1016/j.chest.2019.03.001. No abstract available.

PMID:
31174651
5.

Response.

Lip GYH, Ruff CT, Moores L; 2018 CHEST guideline Expert Panel.

Chest. 2019 Jun;155(6):1307. doi: 10.1016/j.chest.2019.02.329. No abstract available.

PMID:
31174649
6.

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2516-2527. doi: 10.1161/CIRCULATIONAHA.119.039996. Epub 2019 Mar 18.

PMID:
30882239
7.

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.

Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.

PMID:
30882238
8.

Stroke prevention in atrial fibrillation: Closing the gap.

Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, DiBattiste P, Healey JS, Hedrich O, Hylek EM, Kline-Rogers E, Peterson ED, Mendys P, Mirro MJ, Naccarelli G, Patel P, Ruff CT, Rutman H, Stockbridge N, Temple R, Granger CB.

Am Heart J. 2019 Apr;210:29-38. doi: 10.1016/j.ahj.2018.10.004. Epub 2018 Oct 25. No abstract available.

PMID:
30731371
9.

Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial.

Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Eur Heart J. 2019 May 14;40(19):1541-1550. doi: 10.1093/eurheartj/ehy861.

PMID:
30624719
10.

Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial.

Chao TF, Chen SA, Ruff CT, Hamershock RA, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Eur Heart J. 2019 May 14;40(19):1518-1527. doi: 10.1093/eurheartj/ehy807.

PMID:
30590425
11.

Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.

Berg DD, Ruff CT, Jarolim P, Giugliano RP, Nordio F, Lanz HJ, Mercuri MF, Antman EM, Braunwald E, Morrow DA.

Circulation. 2019 Feb 5;139(6):760-771. doi: 10.1161/CIRCULATIONAHA.118.038312.

PMID:
30586727
12.

Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.

Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee and Investigators.

Circulation. 2019 Jan 15;139(3):366-375. doi: 10.1161/CIRCULATIONAHA.118.038341.

PMID:
30586726
13.

Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Braunwald E, Hamershock RA, Murphy SA, Nieminen M, Lanz HJ, Mercuri MF, Peterson N, Antman EM, Giugliano RP.

Europace. 2019 Feb 1;21(2):306-312. doi: 10.1093/europace/euy253.

PMID:
30462220
14.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators.

N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10.

PMID:
30415602
15.

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.

Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, Sritara P, Mercuri MF, Kamphuisen PW, Antman EM, Braunwald E, Giugliano RP.

J Am Heart Assoc. 2018 Aug 21;7(16):e008987. doi: 10.1161/JAHA.118.008987.

16.

The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials.

Zelniker TA, Ruff CT, Antman EM, Giugliano RP.

Eur Heart J Acute Cardiovasc Care. 2018 Oct 15:2048872618796990. doi: 10.1177/2048872618796990. [Epub ahead of print]

PMID:
30318902
17.

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.

Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD; CAMELLIA-TIMI 61 Steering Committee Investigators.

Lancet. 2018 Nov 24;392(10161):2269-2279. doi: 10.1016/S0140-6736(18)32328-6. Epub 2018 Oct 4.

18.

Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.

Corbalán R, Nicolau JC, López-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, Horna M, Ruff CT, Hamershock RA, Grip LT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2018 Sep 25;72(13):1466-1475. doi: 10.1016/j.jacc.2018.07.037.

PMID:
30236308
19.

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.

Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM; CAMELLIA–TIMI 61 Steering Committee and Investigators.

N Engl J Med. 2018 Sep 20;379(12):1107-1117. doi: 10.1056/NEJMoa1808721. Epub 2018 Aug 26.

20.

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.

Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L.

Chest. 2018 Nov;154(5):1121-1201. doi: 10.1016/j.chest.2018.07.040. Epub 2018 Aug 22.

PMID:
30144419
21.

TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation.

Pérez Cabeza AI, Bravo Marques R, Chinchurreta Capote PA, Ruiz Mateas F, Fanola CL, Rosas Cervantes G, González Correa JA, Valle Alberca A, Mesa Prado F, López Tejero S, Ruff CT.

Clin Cardiol. 2018 Sep;41(9):1252-1258. doi: 10.1002/clc.23035. Epub 2018 Aug 20.

22.

Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.

Zelniker TA, Ruff CT, Wiviott SD, Blanc JJ, Cappato R, Nordio F, Mercuri MF, Lanz H, Antman EM, Braunwald E, Giugliano RP.

Eur Heart J Acute Cardiovasc Care. 2019 Mar;8(2):176-185. doi: 10.1177/2048872618790561. Epub 2018 Jul 24.

PMID:
30039978
23.

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.

Yin OQP, Antman EM, Braunwald E, Mercuri MF, Miller R, Morrow D, Ruff CT, Truitt K, Weitz JI, Giugliano RP.

Circulation. 2018 Oct 30;138(18):1963-1973. doi: 10.1161/CIRCULATIONAHA.118.033933.

PMID:
29967197
24.

Pharmacogenetics of Warfarin Therapy.

Ruff CT.

Clin Chem. 2018 Nov;64(11):1558-1559. doi: 10.1373/clinchem.2017.284927. Epub 2018 Jun 25. No abstract available.

PMID:
29941467
25.

Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).

Aisenberg J, Chatterjee-Murphy P, Friedman Flack K, Weitz JI, Ruff CT, Nordio F, Mercuri MF, Choi Y, Antman EM, Braunwald E, Giugliano RP.

Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e003998. doi: 10.1161/CIRCOUTCOMES.117.003998.

PMID:
29748353
26.

Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.

Douketis JD, Murphy SA, Antman EM, Grip LT, Mercuri MF, Ruff CT, Weitz JI, Braunwald E, Giugliano RP.

Thromb Haemost. 2018 Jun;118(6):1001-1008. doi: 10.1055/s-0038-1645856. Epub 2018 May 3.

PMID:
29723874
27.

Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.

Cavallari I, Ruff CT, Nordio F, Deenadayalu N, Shi M, Lanz H, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP.

Int J Cardiol. 2018 Apr 15;257:102-107. doi: 10.1016/j.ijcard.2018.01.065. Epub 2018 Feb 2.

PMID:
29395361
28.

Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials.

Ravvaz K, Weissert JA, Ruff CT, Chi CL, Tonellato PJ.

Circ Cardiovasc Genet. 2017 Dec;10(6). pii: e001804. doi: 10.1161/CIRCGENETICS.117.001804.

29.

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.

Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, Giugliano RP, Cohen DJ, Magnuson EA; ENGAGE AF‐TIMI 48 Trial Investigators.

J Am Heart Assoc. 2017 Aug 11;6(8). pii: e006703. doi: 10.1161/JAHA.117.006703.

30.

Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.

Eisen A, Ruff CT, Braunwald E, Hamershock RA, Lewis BS, Hassager C, Chao TF, Le Heuzey JY, Mercuri M, Rutman H, Antman EM, Giugliano RP.

J Am Heart Assoc. 2017 Jun 30;6(7). pii: e006035. doi: 10.1161/JAHA.117.006035.

31.

First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.

Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP.

Int J Cardiol. 2017 Oct 1;244:192-195. doi: 10.1016/j.ijcard.2017.05.098. Epub 2017 Jun 2.

PMID:
28625512
32.

Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.

De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, Ruff CT, Antman EM, Braunwald E, Giugliano RP.

J Am Coll Cardiol. 2017 Mar 21;69(11):1372-1382. doi: 10.1016/j.jacc.2016.12.031. Erratum in: J Am Coll Cardiol. 2019 Feb 12;73(5):627.

33.

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.

Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman E, Giugliano RP; ENGAGE AF-TIMI 48 Investigators.

Circulation. 2017 Mar 28;135(13):1273-1275. doi: 10.1161/CIRCULATIONAHA.116.026714. Epub 2017 Feb 16. No abstract available.

PMID:
28209729
34.

The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.

Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, Alexander JH, Kowey PR, Ruff CT, Flaker G, Halperin JL, Hart RG, Lopes RD.

JAMA Cardiol. 2017 Mar 1;2(3):324-331. doi: 10.1001/jamacardio.2016.5167. Review.

PMID:
28097334
35.

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, Crompton AE, Murphy SA, Lanz H, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Circ Arrhythm Electrophysiol. 2017 Jan;10(1). pii: e004267. doi: 10.1161/CIRCEP.116.004267.

PMID:
28077507
36.

A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.

Fanola CL, Giugliano RP, Ruff CT, Trevisan M, Nordio F, Mercuri MF, Antman EM, Braunwald E.

Eur Heart J. 2017 Mar 21;38(12):888-896. doi: 10.1093/eurheartj/ehw565.

PMID:
28064150
37.

Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial.

Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, Mercuri M, Antman EM, Morrow DA.

JAMA Cardiol. 2016 Dec 1;1(9):999-1006. doi: 10.1001/jamacardio.2016.3311.

PMID:
27706467
38.

The Reality of "Real-World" Data: More Questions Than Answers.

Ruff CT.

J Am Coll Cardiol. 2016 Sep 27;68(13):1402-1403. doi: 10.1016/j.jacc.2016.06.063. No abstract available.

39.

Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.

Plitt A, Ruff CT, Giugliano RP.

Hematol Oncol Clin North Am. 2016 Oct;30(5):1019-34. doi: 10.1016/j.hoc.2016.05.002. Review.

PMID:
27637305
40.

Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.

Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.

J Am Coll Cardiol. 2016 Sep 13;68(11):1169-1178. doi: 10.1016/j.jacc.2016.06.034. Erratum in: J Am Coll Cardiol. 2017 Jul 25;70(4):512-513.

41.

Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.

Ruff CT, Giugliano RP, Antman EM.

Circulation. 2016 Jul 19;134(3):248-61. doi: 10.1161/CIRCULATIONAHA.116.021831. Review.

PMID:
27436881
42.

Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial.

Eisen A, Ruff CT, Braunwald E, Nordio F, Corbalán R, Dalby A, Dorobantu M, Mercuri M, Lanz H, Rutman H, Wiviott SD, Antman EM, Giugliano RP.

J Am Heart Assoc. 2016 Jul 8;5(7). pii: e003735. doi: 10.1161/JAHA.116.003735.

43.

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Stroke. 2016 Aug;47(8):2075-82. doi: 10.1161/STROKEAHA.116.013540. Epub 2016 Jul 7.

PMID:
27387994
44.

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.

Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E.

Circulation. 2016 Jul 5;134(1):24-36. doi: 10.1161/CIRCULATIONAHA.116.022361.

PMID:
27358434
45.

Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.

Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E.

Eur J Heart Fail. 2016 Sep;18(9):1153-61. doi: 10.1002/ejhf.595. Epub 2016 Jun 28.

46.

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.

Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, Nordio F, Murphy SA, Kimura T, Jin J, Lanz H, Mercuri M, Braunwald E, Antman EM.

J Am Heart Assoc. 2016 May 20;5(5). pii: e003432. doi: 10.1161/JAHA.116.003432.

47.

North American Thrombosis Forum, AF Action Initiative Consensus Document.

Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI.

Am J Med. 2016 May;129(5 Suppl):S1-S29. doi: 10.1016/j.amjmed.2016.02.001.

PMID:
27126598
48.

The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.

Gupta DK, Giugliano RP, Ruff CT, Claggett B, Murphy S, Antman E, Mercuri MF, Braunwald E, Solomon SD; Effective Anticoagulation with Factor Xa Next Generation in AF–Thrombolysis in Myocardial Infarction 48 (ENGAGE AF–IMI 48) Echocardiographic Study Investigators.

J Am Soc Echocardiogr. 2016 Jun;29(6):537-44. doi: 10.1016/j.echo.2016.03.004. Epub 2016 Apr 20.

49.

Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.

Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M, Mercuri MF, Antman EM, Braunwald E.

Am J Med. 2016 Aug;129(8):850-857.e2. doi: 10.1016/j.amjmed.2016.02.028. Epub 2016 Mar 17.

50.

Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial.

Krekels EH, Niebecker R, Karlsson MO, Miller R, Shimizu T, Karlsson KE, Ruff CT, Simonsson US, Jönsson S.

Clin Pharmacokinet. 2016 Sep;55(9):1079-90. doi: 10.1007/s40262-016-0378-3.

PMID:
26951208

Supplemental Content

Support Center